ReviewBMC nephrology2025
Distal renal tubular acidosis triggered by clozapine in a patient with a heterozygous ATP6V0A4 c.1029 + 5G > A variant: a case report and literature review.
Review in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDistal renal tubular acidosis (dRTA) is characterized by impaired acidification in the distal tubules and may be associated with genetic factors, such as ATP6V0A4 variants. The role of clozapine in triggering dRTA, particularly in individuals with underlying genetic susceptibility, remains poorly understood. CASE PRESENTATION: A 24-year-old woman with schizophrenia developed dRTA following the reintroduction of clozapine; a previous episode had resolved after discontinuation of the drug. Investigations confirmed impaired urinary acidification consistent with dRTA. Genetic testing identified a heterozygous ATP6V0A4 variant (c.1029 + 5G > A). She responded well to sodium bicarbonate therapy, which enabled the continuation of clozapine treatment.
conclusionThis case highlights a potential gene-drug interaction, in which an ATP6V0A4 variant predisposed the patient to clozapine-induced dRTA. Recognizing genetic susceptibility is essential when dRTA arises in the context of medications not typically associated with the condition, to inform both diagnosis and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.